Kawthar Bohliagah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kawthar Bohliagah has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Abdurahman Saud Al Arfaj
Rheumatology Unit, Department of Medicine, College of Medicine, King Saud University, Riyadh 11461, Saudi Arabia
1 shared publication - Aos Aboabat
Rheumatology Unit, Department of Medicine, College of Medicine, King Saud University, Riyadh 11461, Saudi Arabia
1 shared publication - Fehaid Alanazi
Rheumatology Unit, Department of Medicine, College of Medicine, King Saud University, Riyadh 11461, Saudi Arabia
1 shared publication - Haya Mohammed Almalag
Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia
1 shared publication - Hebatallah Hamed Ali
College of Medicine Research Center, College of Medicine, King Saud University, Riyadh 11451, Saudi Arabia
1 shared publication - Ibrahim Almaghlouth
Rheumatology Unit, Department of Medicine, College of Medicine, King Saud University, Riyadh 11461, Saudi Arabia
1 shared publication
Latest Publications
- Open Access
- 7 June 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (12) , 4409
The Relationship Between Lipid Profile as a Cardiovascular Risk Factor and Patient-Reported Physical Activity Scores: An Exploratory Analysis from the Saudi Systemic Lupus Erythematosus Cohort
Background: Systemic lupus erythematosus (SLE) is associated with an increased burden of cardiovascular disease (CVD), driven by dyslipidemia, hypertension, obesity, inflammation, and treatment. These factors can impact patient quality of life (QoL) by limiting physical activity. Objectives: To characterize lipid abnormalities as CVD risk factors in a Saudi SLE cohort and assess associations between lipid profile, SLE features, treatment, and patient-reported outcomes of physical activity. Methods: A cohort of adult SLE patients followed at King Saud University Medical City since 2021 was analyzed. Demographics, lipid profiles, blood pressure, BMI, SLEDAI-2K, SDI, disease duration, and treatment data were collected. Physical function and quality of life were assessed using the LupusQoL and PROMIS Physical Function T scores. Univariate and multivariate logistic regression analyses were conducted to identify associations between lipid abnormalities, SLE-related factors, and QoL physical activity measures. Results: A cohort of 169 patients (88.2% female, mean age 39.3 ± 12.4 years) was evaluated to assess the presence of dyslipidemia (23.7%), obesity (BMI ≥ 25, 66.3%), and hypertension (≥130/80 mmHg, 26.0%). Mean SLE duration was 9.2 ± 7.7 years and mean SLEDAI-2K was 11.0 ± 7.0. Among these patients, 52.7% used steroids, 88.2% used antimalarial drugs, and 53.8% used immunosuppressives. Dyslipidemia was associated with lower LupusQoL physical scores (adjusted OR 0.986; 95% CI 0.972–1.000; p = 0.0446). No significant associations were found between lipid levels and the PROMIS Physical Function T score. Conclusions: In this Saudi SLE cohort, dyslipidemia and other modifiable CVD risks were common. Dyslipidemia correlated with poorer LupusQoL-specific physical scores, which highlights the importance of lifestyle changes in patients with SLE.
- 7 June 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (12) , 4409
Open AccessThe Relationship Between Lipid Profile as a Cardiovascular Risk Factor and Patient-Reported Physical Activity Scores: An Exploratory Analysis from the Saudi Systemic Lupus Erythematosus Cohort
Background: Systemic lupus erythematosus (SLE) is associated with an increased burden of cardiovascular disease (CVD), driven by dyslipidemia, hypertension, obesity, inflammation, and treatment. These factors can impact patient quality of life (QoL) by limiting physical activity. Objectives: To characterize lipid abnormalities as CVD risk factors in a Saudi SLE cohort and assess associations between lipid profile, SLE features, treatment, and patient-reported outcomes of physical activity. Methods: A cohort of adult SLE patients followed at King Saud University Medical City since 2021 was analyzed. Demographics, lipid profiles, blood pressure, BMI, SLEDAI-2K, SDI, disease duration, and treatment data were collected. Physical function and quality of life were assessed using the LupusQoL and PROMIS Physical Function T scores. Univariate and multivariate logistic regression analyses were conducted to identify associations between lipid abnormalities, SLE-related factors, and QoL physical activity measures. Results: A cohort of 169 patients (88.2% female, mean age 39.3 ± 12.4 years) was evaluated to assess the presence of dyslipidemia (23.7%), obesity (BMI ≥ 25, 66.3%), and hypertension (≥130/80 mmHg, 26.0%). Mean SLE duration was 9.2 ± 7.7 years and mean SLEDAI-2K was 11.0 ± 7.0. Among these patients, 52.7% used steroids, 88.2% used antimalarial drugs, and 53.8% used immunosuppressives. Dyslipidemia was associated with lower LupusQoL physical scores (adjusted OR 0.986; 95% CI 0.972–1.000; p = 0.0446). No significant associations were found between lipid levels and the PROMIS Physical Function T score. Conclusions: In this Saudi SLE cohort, dyslipidemia and other modifiable CVD risks were common. Dyslipidemia correlated with poorer LupusQoL-specific physical scores, which highlights the importance of lifestyle changes in patients with SLE.